PROTOTYPE SELF EMULSIFYING SYSTEM OF ETRAVIRINE: DESIGN, FORMULATION AND IN VITRO EVALUATION
Objective: Lipid-based formulations have gained much attention, particularly on self-emulsifying drug delivery systems (SEDDS), to improve the oral bioavailability of lipophilic drugs. In the present study, an attempt was made to develop and evaluate prototype SEDDS of poorly soluble antiviral BCS class IV drug etravirine.
Methods: Various oils, surfactants and co-surfactants were screened for their suitability in the formulation of SEDDS. Based on the screening, gelucire 44/14, as the oil, labrasol as a surfactant and transcutol HP as the co-surfactant were selected. SEDDS with drug etravirine was formulated and evaluated for emulsifying ability, dilution potential and microscopic properties. The emulsion area for each of the combination of oil and surfactant co-surfactant mixture (Smix) was determined by the construction of pseudo-ternary phase diagrams.
Results: The optimized formulation with oil (gelucire 44/14) and Smix (labrasol: transcutol HP, 6:1) in a ratio of 2:8 exhibited a rapid emulsification rate and a good polydispersibility index of 0.103Â±0.012 indicating uniformity of the formed droplets. The size of the droplets was determined by zetasizer and was found to be in 200 nm range. The drug release from the final formulation after 2hr was found to be 41.15%Â±0.5 compared to 19.3%Â±3.8 of pure drug indicating enhanced dissolution profile of the drug.
Conclusion: In vitro study illustrated enhanced dissolution rate of formulated prototype SEDDS of BCS class IV drug etravirine for oral delivery.
2. Archita P, Anita L. Self micro emulsifying drug delivery system as a potential drug delivery system for protease inhibitors in the treatment of AIDS. Asian J Pharm 2011;6:226-40.
3. Umesh G, Narendra KJ. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Adv Drug Delivery Rev 2010;62:478-90.
4. Marie PB. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 y (1989â€“2009). Antiviral Res 2010;85:75â€“90.
5. Schiller DS, Youssef-Bessler M. Etravirine: a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. Clin Ther 2009;31:692-704.
6. Jessica A, Nimish P, Nancy, Mariam T, Christopher DM. Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents. Ann Pharmacother 2010;44:157-65.
7. Leonard B Johnson, Louis D Saravolatz. Etravirine, a next-generation non-nucleoside reverse-transcriptase inhibitor. Clin Infect Dis 2009;48:1123-8.
8. Yohei K, Koichi W, Manabu N, Shizuo Y, Satomi O. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm 2011;420:1-10.
9. Sandeep K, Mohanvarma M, Veerabhadhraswamy P. Oral lipid-based drug delivery systemsâ€“an overview. Acta Pharm Sinica B 2013;3:361â€“72.
10. Colin W Pouton. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and â€˜self-micro emulsifyingâ€™ drug delivery systems. Eur J Pharm Sci 2000;11 Suppl 2:S93â€“8.
11. Christopher JH Porter, Colin WP, Jean F Cuine, William NC. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Delivery Rev 2008;60:673â€“91.
12. Jaime AY, Stephen WJ Wang, Ian WK, Mark AW, Kevin BA. Intestinal lymphatic transport for drug delivery. Adv Drug Delivery Rev 201;163:923â€“42.
13. Anne C, Thomas B, Werner W. Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes. Eur J Pharm Sci 2010;41:376â€“82.
14. Gershanik T, Benita S. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm 2000;50:179-88.
15. Mohd JQ, Chitneni M, Wong GK. Enhancement of solubility and therapeutic potential of poorly soluble lovastatin by SMEDDS formulation adsorbed on directly compressed spray dried magnesium aluminometasilicate liquid loadable tablets: a study in diet-induced hyperlipidemic rabbits. Asian J Pharm 2015;10:40â€“56.
16. Naser MY Hasan. Role of medium-chain fatty acids in the emulsification mechanistics of self-micro-emulsifying lipid formulations. Saudi Pharm J 2014;22:580â€“90.
17. R Neslihan Gursoy, Simon B. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 2004;58:173â€“82.
18. Zupancic O, GrieÎ²inger JA, Rohrer J, Pereira de Sousa I, Danninger L, Partenhauser A, et al. Development in vitro and in vivo evaluation of a self-emulsifying drug delivery system (SEDDS) for oral enoxaparin administration. Eur J Pharm Biopharm 2016;109:113-21.
19. Huiyi W, Xiaoying L, FeiYuana, Li C, Sujing P, Yunjun L, et al. Combined use of phospholipid complexes and self-emulsifying microemulsions for improving the oral absorption of a BCS class IV compound, baicalin. Acta Pharm Sin B 2014;4:217â€“26.
20. Shweta G, Sandip C, Krutika KS. Self-nanoemulsifying drug delivery system for adefovir dipivoxil: design, characterization, in vitro and ex vivo evaluation. Colloids Surf A 2011;392:145â€“55.
21. Prajapati HN, Dalrymple DM, Serajuddin AT. A comparative evaluation of mono-, di-and triglyceride of medium chain fatty acids by lipid/surfactant/water phase diagram, solubility determination and dispersion testing for application in pharmaceutical dosage form development. Pharm Res 2012;29:285-305.
22. Prakash CS, Sunit KS, Alakh NS. Mixed surfactant based (SNEDDS) self-nanoemulsifying drug delivery system presenting efavirenz for enhancement of oral bioavailability. Bâ€Žiomed Pharmacother 2016;80:42â€“51.
23. Kotta S, Khan AW, Ansari SH, Sharma RK, Ali J. Anti HIV nanoemulsion formulation: Optimization and in vitroâ€“in vivo evaluation. Int J Pharm 2014;462:129-34.
24. Shubham R, Mohd Y. Cinnarizine loaded lipid-based system: preparation, optimization and inâ€“vitro evaluation. J Pharm 2012;2:47-56.
25. Meena AK, Sharma K, Kandaswamy M, Rajagopal S, Mullangi R. Formulation development of an albendazole self-emulsifying drug delivery system (SEDDS) with enhanced systemic exposure. Acta Pharm 2012;62:563-80.
26. Amit AK, Vandana BP. Design and evaluation of self-emulsifying drug delivery systems (SEDDS) of nimodipine. AAPS PharmSciTech 2008;9:191â€“6.
27. Patel D, Sawant KK. Oral bioavailability enhancement of acyclovir by self-micro emulsifying drug delivery systems (SMEDDS). Drug Dev Ind Pharm 200;33:1318-26.
28. Soliman MS, Khan MA. Preparation and in vitro characterization of a semi-solid dispersion of flurbiprofen with Gelucire 44/14 and Labrasol. Pharmazie 2005;60:288-93.
29. Jannin V, Musakhanian J, Marchaud D. Approaches for the development of solid and semi-solid lipid-based formulations. Adv Drug Delivery Rev 2008;60:734-46.
30. Gershanik T, Benita S. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm 2000;50:179-88.
31. Syed HK, Peh KK. Identification of phases of various oil, surfactant/co-surfactants and water system by ternary phase diagram. Acta Pol Pharm 2014;71:301-9.
32. Venkata RK, Basanth BE, Raju J, Ram KA, Suresh B. A gelucire 44/14 and labrasol based solid self-emulsifying drug delivery system: formulation and evaluation. J Pharm Investig 2013; 43:185â€“96.
33. YÃ¼ksel N, KarataÅŸ A, Ozkan Y, SavaÅŸer A, Ozkan SA, Baykara T. Enhanced bioavailability of piroxicam using Gelucire 44/14 and labrasol: in vitro and in vivo evaluation. Eur J Pharm Biopharm 2003;56:453-9.
34. Koga K, Kusawake Y, Ito Y, Sugioka N, Shibata N, Takada K. Enhancing mechanism of Labrasol on intestinal membrane permeability of the hydrophilic drug gentamicin sulfate. Eur J Pharm Biopharm 2006;64:82-91.
35. Prasad YV, Puthli SP, Eaimtrakarn S, Ishida M, Yoshikawa Y, Shibata N, et al. Enhanced intestinal absorption of vancomycin with Labrasol and D-a-tocopheryl PEG 1000 succinate in rats. Int J Pharm 2003;250:181-90.
36. Delongeas JL, de Conchard GV, Beamonte A, Bertheux H, Spire C, Maisonneuve C, et al. Assessment of Labrasol_/ labrafil_/Transcutol_ (4/4/2, v/v/v) as a non-clinical vehicle for poorly water-soluble compounds after 4-week oral toxicity study in wistar rats. Regul Toxicol Pharmacol 2010;57:284-90.
37. Mura P, Faucci MT, Bramanti G, Corti P. Evaluation of transcutol as a clonazepam transdermal permeation enhancer from hydrophilic gel formulations. Eur J Pharm Sci 2000;9:365-72.
38. Mahmoud DB, Shukr MH, Bendas ER. In vitro and in vivo evaluation of self-nano emulsifying drug delivery systems of cilostazol for oral and parenteral administration. Int J Pharm 2014;476:60-9.
39. Lee DH, Yeom DW, Song YS, Cho HR, Choi YS, et al. Improved oral absorption of dutasteride via Soluplus1-based supersaturable self-emulsifying drug delivery system (S-SEDDS). Int J Pharm 2015;478:341-7.
40. Nahla SB. Enhanced oral bioavailability of etodolac by self-emulsifying systems: in vitro and in vivo evaluation. J Pharm Pharmacol 2010;62:173â€“80.
41. Jaydeep P, Anjali P, Mihir R, Navin S. Formulation and development of a self-nanoemulsifying drug delivery system of irbesartan. J Adv Pharm Technol Res 2011;2:9â€“16.